Ollin Biosciences raised $330 million in a Series B to advance a Phase 3 program for its eye-disease therapy targeting both diabetic macular edema and wet age-related macular degeneration. The company said it plans to begin the pivotal trial soon, framing the raise as funding for late-stage execution. The Series B was co-led by TCGX and ARCH Venture Partners and included participation from established biotech investors, a pension fund, and crossover investors. Ollin told investors the funding follows head-to-head data suggesting its licensed-from-a-China-developer drug had advantages over Roche’s Vabysmo. Ollin is positioning the asset against a large retinal market where late-stage data and regulatory strategy will be decisive. The financing underscores that investors are still backing differentiated ocular programs moving toward Phase 3.